GLPG-0634 is a triazolopyridine that inhibits JAK1; it exhibits anti-inflammatory and immunomodulatory activities. GLPG-0634 prevents release of inflammatory cytokines and is currently under investigation as a potential treatment for rheumatoid arthritis and Crohn’s disease.
| Cas No. | 1206161-97-8 |
|---|---|
| Purity | ≥98% |
| Formula | C21H23N5O3S |
| Formula Wt. | 425.50 |
| IUPAC Name | N-(5-{4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide |
| Synonym | GLPG0634, Filgotinib |
| Solubility | DMSO 0.1 mg/mL (0.24 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clin Pharmacokinet. 2015 Feb 14. [Epub ahead of print]. PMID: 25681059.
Menet CJ, Fletcher SR, Van Lommen G, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 2014 Nov 26;57(22):9323-42. PMID: 25369270.
Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. PMID: 24818516.
